T NFR1 signalling involves the formation of two distinct complexes 1 . The plasma membrane-associated TNFR1-SC, also termed complex-I, is responsible for gene activation, whereas the subsequently formed cytosolic complex-II induces cell death. Under physiological conditions, TNFR1 stimulation induces gene activation rather than cell death. However, aberrant TNF-induced signalling causes several autoimmune pathologies and cancerrelated inflammation 2,3 . Therefore, defining the molecular checkpoints that determine the different TNFR1 signalling outputs is critical to understand the biology of inflammation.
A western blot analysis revealed that TBK1 and IKKε are recruited to and strongly phosphorylated within the native TNFR1-SC on the activatory S172 residue 38 in various HOIP-proficient cell lines, whereas their activation in corresponding HOIP-deficient cells is very weak (Fig. 1b,c; Supplementary Fig. 1a,b ). Thus, TBK1 and IKKε are bona fide components of complex-I, and LUBAC enables their recruitment. 
Fig. 1 | LuBAC mediates the recruitment and activation of the non-canonical kinases TBK1
and IKKε in the TNFR1-SC. a, A549 HOIP control or HOIPdeficient (HOIP KO) cells were stimulated with TAP-TNF (500 ng ml -1 ) for 15 min. TNFR1-SC was purified in a two-step immunoprecipitation process via TAP-Tag and analysed by LC-MS/MS. The mean protein abundance for two independent experiments and two LC-MS analyses is plotted as indicated. Raw data can be accessed at the ProteomeXchange Consortium via the PRIDE 70 partner repository with the dataset identifier PXD008497; analysed data are provided in Supplementary Table 2 . b, A549, HaCaT, U937 and THP-1 cells were stimulated with FLAG-TNF (1 µ g ml -1 ) for the indicated times. TNFR1-SC was purified and analysed by western blotting. c, HeLa HOIP control or HOIP-deficient cells were stimulated with TAP-TNF (500 ng ml -1 ) and subjected to TNFR1-SC isolation and western blot analysis. d, HOIP-deficient A549 cells were reconstituted with empty vector, HOIP WT or enzymatically inactive HOIP C885S and were stimulated with TNF (200 ng ml -1 ) for the indicated times, and lysates were analysed by western blotting. e, HOIP-deficient A549 cells reconstituted with empty vector, HOIP WT or enzymatically inactive HOIP C885S were stimulated with FLAG-TNF (1 µ g ml -1 ) for the indicated time. Lysates and TNFR1-SC were analysed by western blotting. For b-e, one representative experiment out of two is shown. Unprocessed original scans of blots are shown in Supplementary Fig. 7 .
Using HOIP-deficient HeLa and A549 cells reconstituted with wild-type HOIP (HOIP WT ) or catalytically inactive HOIP (HOIP C885S ) 39 , we determined that effective TBK1 and IKKε recruitment to complex-I requires the M1 ubiquitin-forming activity of LUBAC, as TBK1 and IKKε recruitment was strongly diminished in HOIP-deficient HeLa and A549 cells whether or not HOIP C885S was re-expressed in them ( Fig. 1d,e; Supplementary Fig. 1c,d) .
The role of TBK1 and IKKε in TNF-induced gene activation is limited. As TBK1 and IKKε are crucial for gene expression by various immune receptor complexes 30, [40] [41] [42] , we evaluated whether these kinases influenced TNF-induced gene activation by generating L929 cells in which TBK1, IKKε and TNF are all knocked out. The absence of TBK1 and IKKε did not significantly affect TNF-induced gene activatory signalling and, if anything, slightly increased Iκ Bα phosphorylation ( Supplementary Fig. 2a ). This result is in line with the previously proposed roles of TBK1 and IKKε as negative regulators of IKKα and IKKβ activation 43 . Similarly, in mouse embryonic fibroblasts (MEFs) and A549 cells, treatment with the TBK1 and IKKε -specific inhibitor MRT67307 43 (MRT) did not exert any significant effects on the TNF-induced activation of MAPKs or NF-κ B ( Fig. 2a; Supplementary Fig. 2b ). Next, we evaluated whether TBK1 and IKKε affect gene induction following TNFR1 stimulation. We performed an unbiased RNA sequencing (RNA-seq) analysis following TNF versus TNF plus MRT stimulation, also including TNF and TPCA-1, which, as an IKKα and IKKβ -inhibiting control, is known to profoundly affect TNF-induced gene expression 44 . wild-type (WT) cells were preincubated with either vehicle (DMSO) or MRT for 30 min, followed by stimulation with TNF (200 ng ml -1 ) for the indicated times. a, Lysates were analysed by western blotting. One representative experiment out of two is shown. The asterisk indicates staining from previous p-JNK. Unprocessed original scans of blots are shown in Supplementary Fig. 7 . b-d, Cells were lysed, their total RNA extracted and RNA-seq analysis performed. Samples from three independent experiments were obtained and analysed. A principal component (PC) analysis of A549 samples based on transcriptome-wide expression level data is shown (b). The heatmap (c) illustrates the major change of expression across the dataset. The genes shown are the 100 that were most highly correlated with PC1 (see b). To increase the clarity of the comparison, the rlog (regularised logs to normalise read counts) expression data of each row were zeroed at time point 0 h and then scaled by the standard deviation. The RNA-seq raw dataset for b and c are available in the SRA repository and can be accessed using the BioProject accession number PRJNA422567 or SRA accession number SRP126844 (https://www.ncbi.nlm.nih.gov/ Traces/study/?acc= SRP126844). The Venn diagram (d) represents the number of all transcripts significantly regulated following 1 h of TNF stimulation in samples treated with vehicle, MRT or TPCA-1 and the transcript overlap between these three groups. Corresponding transcripts can be found in Supplementary Table 3 . Differential RNA-seq expression statistics (P values) on contrasting biological triplicates, corresponding to samples obtained from three independent experiments (groups as in b-d), were estimated using DESeq2. Adjusted P value statistics were calculated using the Benjamini-Hochberg and IHW adjustment.
A principal component analysis revealed that TNF drastically modulated gene expression, with TNF-treated cells clearly segregated from untreated samples. While the effect of IKKα and IKKβ inhibition on TNF-induced gene expression was substantial, the effect of TBK1 and IKKε inhibition was surprisingly limited (Fig. 2b) . The top 100 most altered transcripts were highly similar Supplementary Table 1 .
between TNF-stimulated control cells and TNF and MRT-treated cells, but significantly different in TNF and TPCA-1-treated cells ( Fig. 2c ; Supplementary Fig. 2c ). Notably, the majority of transcripts with significantly altered expression at the 1-h time point in control cells were similarly modulated in TNF and MRT-treated cells but not in TNF and TPCA-1-treated cells ( Fig. 2d ; Supplementary  Table 3 ). Thus, in contrast to the roles of TBK1 and IKKε as drivers of gene induction in other immune signalling pathways 40, 41 , their role in TNF-induced gene expression is limited.
TBK1 and IKKε prevent TNF-induced RIPK1-dependent cell death. We next assessed the role of TBK1 and IKKε in TNF-induced cell death. Strikingly, treatment with MRT or another TBK1 and IKKε -specific inhibitor, BX-795 45 , drastically sensitized MEFs and L929 cells to TNF-induced death ( Fig. 3a,b ; Supplementary Fig. 3a ). Intriguingly, in both cases, cell death was prevented by the RIPK1
inhibitor Nec-1s ( Fig. 3a,b ; Supplementary Fig. 3a ). Interestingly, the MRT-induced spontaneous death of L929 cells was inhibited by the TNF blocker etanercept (also known as Enbrel; Supplementary  Fig. 3b ). Next, we created TNF-deficient MEFs and L929 cells in which we further deleted TBK1, IKKε or both kinases to enable us to genetically assess their cell death-preventive function. In line with the results obtained when these kinases were inhibited, concomitant deletion of TBK1 and IKKε strongly sensitized these cells to TNF-induced death ( Fig. 3c ; Supplementary Fig. 3c,d ). Thus, both pharmacological inhibition and genetic ablation of TBK1 and IKKε sensitizes cells to TNF-induced death. We next investigated the cell death modality induced by TBK1 and IKKε inhibition. While pretreatment with the pan-caspase inhibitor zVAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[Omethyl]-fluoromethylketone) substantially sensitized MEFs to TNF alone, sensitization to TNF and MRT was significantly higher pretreated with or without BX-795 were stimulated with TNF (1 µ g ml -1 ) and zVAD-FMK for 15 min before RIPK1 pull down. RIPK1 immunoprecipitate (IP) treated with USP2 and λ -phosphatase (λ PP) as indicated was analysed by western blotting. b, L929 cells were stimulated with TAP-TNF for 15 min (1 µ g ml -1 ) with or without MRT. TNFR1-SC was FLAG-immunoprecipitated. Samples were first separated by pI on IPG strips pH 3-10 NL, followed by SDS-PAGE and western blot analysis. c, Indicated MEFs were treated with FLAG-TNF (1 µ g ml -1 ) and Nec-1s, followed by FLAG-IP. TNFR1-SC treated with USP2 and λ -phosphatase as indicated was analysed by western blotting. d,e, GST-tagged TBK1 (d) and IKKε (e) were incubated with GST-tagged RIPK1 in a kinase assay with or without the indicated inhibitors before western blot analysis. f, Phosphosites identified by LC-MS/MS from one kinase assay using GST-tagged RIPK1, Nec-1s and IKKε . RHIM, RIP homotypic interaction motif. Raw data are accessible at the ProteomeXchange Consortium via the PRIDE 70 partner repository with the dataset identifier PXD008518; analysed data are provided in Supplementary Table 4 . g, TNF -/-MEFs pretreated with indicated inhibitors (i) were stimulated with FLAG-TNF (1 µ g ml -1 ) and Nec-1s for 15 min, followed by FLAG-IP. TNFR1-SCs treated with USP2 and λ -phosphatase as indicated were analysed via western blotting. The asterisks indicate nonspecific bands. h, TNF -/-MEFs pretreated with indicated inhibitors were stimulated with FLAG-TNF (1 µ g ml -1 ) and Nec-1s for 15 min, followed by FLAG-IP. TNFR1-SCs treated with USP2 were first separated by pI on IPG strips pH 4-7 followed by SDS-PAGE and western blot analysis. i, TNF -/-MEFs stimulated with indicated inhibitors for 30 min were treated with TNF (500 ng ml -1 ) for 7 h. j, L929 pre-incubated with Nec-1s for 15 min and further incubated with indicated inhibitors for 30 min were treated with TNF (50 ng ml -1 ) for 4 h. i,j, Loss of cell viability was determined by CTG assay. Mean ± s.e.m. of n = 4 (i) or mean ± s.e.m. of n = 3 (j) independent experiments. k, Cumulative survival rates of mice following TNF-α -induced shock in the presence of indicated inhibitors were compared using log-rank Mantel-Cox tests. MRT versus TNF + MRT, P < 0.001; TNF versus TNF + MRT, P < 0.0001; TNF + MRT versus TNF + MRT + Nec-1s, P = 0.0061. Unprocessed blots are shown in Supplementary Fig. 7 , raw data in Supplementary Table 1 . One experiment representative of two (a-c, g, h) or three (d, e) independent experiments is shown. NAP1, which recruit TBK1 and IKKε, or TBK1 only, respectively, to the TNFR1-SC. a, TANKdeficient A549 cell clones and control cells were treated with TNF (200 ng ml -1 ) for the indicated times. Lysates were analysed by western blotting. b, TANK-deficient or corresponding control A549 cells were stimulated with FLAG-TNF (500 ng ml -1 ) for the indicated times. The purified TNFR1-SC and lysates were analysed by western blotting. c, A549 TBK1-deficient cells were reconstituted with TBK1 WT-TAP . The TBK1 interactome was purified in a two-step immunoprecipitation process via TAP-tag and analysed by LC-MS/MS. One experiment was analysed. Raw data can be accessed at the ProteomeXchange Consortium via the PRIDE 70 partner repository with the dataset identifier PXD010777; analysed data are provided in Supplementary  Table 5 . d, A549 TBK1-deficient cells were reconstituted with TBK1 WT-TAP or the catalytically inactive mutant TBK1 D135N-TAP and treated with TNF (500 ng ml -1 ) as indicated. The purified TBK1-associated complex and lysates were analysed by western blotting. e, HOIP-deficient A549 cells reconstituted with HOIP WT , enzymatically inactive HOIP C885S or vector control were stimulated with FLAG-TNF (500 ng ml -1 ) for the indicated times. The purified TNFR1-SC and lysates were analysed by western blotting. f, HeLa TANK-deficient cells, concomitantly deficient in TANK and NAP1 (TANK/NAP1 DKO), or corresponding control cells were stimulated with TAP-TNF (500 ng ml -1 ) and subjected to immunoprecipitation via Flag. The purified TNFR1-SC and lysates were analysed by western blotting. g, NEMO-deficient and corresponding wild-type MEFs were stimulated with TNF (200 ng ml -1 ) for the indicated times. Lysates were analysed by western blotting. h, A549 control and NEMO-deficient cells were stimulated with HA-TNF (1 µ g ml -1 ) and subjected to immunoprecipitation via HA. The purified TNFR1-SC and lysates were analysed by western blotting. i, A549 NEMO-deficient cells reconstituted with NEMO WT , NEMO ΔTBD or vector control were stimulated with HA-TNF (1 µ g ml -1 ) for the indicated times. The purified TNFR1-SC and lysates were analysed by western blotting. One experiment representative of two (a, b, d-g) or three independent experiments (h, i) is shown. Unprocessed original scans of blots are shown in Supplementary Fig. 7 .
( Fig. 3d; Supplementary Fig. 3e ). Importantly, RIPK1 kinase-dead MEFs were resistant to MRT-induced death sensitization by TNF or TNF plus zVAD-FMK ( Fig. 3e,f ). In line with the finding that LUBAC is required for effective TNF-induced TBK1 and IKKε activation, inhibition of both TBK1 and IKKε did not sensitize HOIP-deficient MEFs to TNF-induced or zVAD-FMK plus TNF-induced cell death (Fig. 3g,h) . Moreover, MRT-mediated sensitization to TNF-induced necroptosis occurred in human A549 cells expressing RIPK3 ( Supplementary Fig. 3f-h) . Notably, MEFs were also sensitized to TNF-induced death in the presence of cycloheximide, indicating that protein synthesis is not necessary for the sensitization mediated by TBK1 and IKKε inhibition ( Supplementary Fig. 3i,j) . MRT also sensitized primary bone marrow-derived macrophages (BMDMs) to TNF-induced RIPK1-dependent death ( Supplementary Fig. 4a ). Again, a substantial percentage of MRT-only-treated BMDMs were killed by endogenous TNF (Supplementary Fig. 4b ). Interestingly, BMDMs were exclusively sensitized to TNF-induced apoptosis ( Supplementary Fig. 4c ). Accordingly, the absence of the necroptosis-mediating pseudokinase MLKL did not diminish TNF and MRT-induced BMDM death, while the ablation of both caspase-8 and MLKL abrogated it ( Supplementary Fig. 4d,e ).
Together, these results demonstrate that the inhibition or absence of TBK1 and IKKε promotes TNF-induced apoptosis and/ or necroptosis, which depends on the ability of a given cell type to undergo death by the respective modality. Importantly, in either case, cell death induction requires the activity of RIPK1.
TBK1 and IKKε prevent TNF-induced RIPK1 activation and ensuing complex-II formation. TNFR1-SC assembly precedes the formation of complex-II, which contains RIPK1, FADD, FLIP, caspase-8, RIPK3 and MLKL. Depending on the cellular context and the relative expression of pro-and anti-apoptotic and pro-and anti-necroptotic proteins 15, [46] [47] [48] , complex-II can trigger apoptosis or necroptosis. RIPK1 kinase activity mediates complex-II formation and is therefore generally required for TNF-induced cell death 17 .
Since the kinase activity of RIPK1 is required for TNF-induced cell death when TBK1 and IKKε are absent or inhibited, we assessed whether TBK1 and IKKε prevent cytotoxicity by preventing RIPK1 from mediating complex-II formation. We treated A549 cells expressing TAP (tandem affinity purification)-tagged RIPK3 with TNF and zVAD-FMK or a combination of TNF, zVAD-FMK and BX-795 before immunoprecipitating RIPK3. TBK1 and IKKε inhibition markedly enhanced the association of RIPK3 with caspase-8 and FADD, phosphorylated MLKL (p-MLKL) and phosphorylated RIPK1 (p-RIPK1) (Fig. 4a ). Enhanced RIPK3 binding to caspase-8 and p-MLKL was also observed in RIPK3-expressing HeLa cells and, decisively, concomitant RIPK1 inhibition prevented complex-II formation (Fig. 4b) .
In accordance with the increased cell death observed following TBK1 and IKKε inhibition, L929 cells and MEFs also displayed increased RIPK1 activation and complex-II formation following TNF, zVAD-FMK and MRT co-treatment ( Fig. 4c,d) . Importantly, genetic TBK1 and IKKε co-ablation in MEFs (Fig. 4e ) and TNF and MRT treatment of primary BMDMs (Fig. 4f ) also substantially enhanced complex-II formation. In all cases, complex-II formation was dependent on RIPK1 kinase activity ( Fig. 4b-f ). Hence, TBK1 and IKKε prevent TNF-induced cell death by restricting RIPK1 autoactivation and consequent complex-II formation.
TBK1 and IKKε mediate phosphorylation of RIPK1 in the TNFR1-SC. We hypothesized that the negative effect of TBK1 and IKKε on RIPK1 autophosphorylation might be achieved via TNFinduced RIPK1 phosphorylation mediated by these kinases. Thus, we determined whether we could detect any TBK1-and IKKεdependent phosphorylation of RIPK1. After immunoprecipitating RIPK1 from L929 cells treated with TNF or TNF and BX-795 in the presence of zVAD-FMK, we incubated the resulting immunoprecipitates with or, as a control, without the pan-deubiquitinase USP2 to completely deubiquitylate RIPK1. This was done with or without λ -phosphatase to uncover any RIPK1 phosphorylation that requires TBK1 and IKKε activity (Fig. 5a ). USP2 treatment resulted in the collapse of most modified high-molecular-weight forms onto low-molecular-weight forms of RIPK1. The intermediate-molecular-weight forms remaining after USP2 treatment completely collapsed onto the band of unmodified RIPK1 following treatment with λ -phosphatase. This result demonstrates that phosphorylation accounts for the TBK1 and IKKε -dependent mobility shift of deubiquitylated RIPK1. Interestingly, TNF and BX-795 co-treatment reduced the RIPK1 mobility shift compared to TNF treatment. Most importantly, this shift was not seen following λ -phosphatase treatment, demonstrating that TBK1 and IKKε inhibition specifically prevents RIPK1 phosphorylation (Fig. 5a ).
To assess whether TBK1-and IKKε -dependent RIPK1 phosphorylation occurs in the TNFR1-SC, we immunoprecipitated complex-I following TNF versus TNF and MRT treatment before evaluating the status of RIPK1 phosphorylation by two-dimensional (2D) gel electrophoresis. This revealed that TBK1 and IKKε inhibition reduced the low isoelectric point (pI) forms of RIPK1 after TNF stimulation in complex-I ( Fig. 5b) . Importantly, RIPK1 phosphorylation in complex-I was also reduced in MEFs and L929 cells in which TNF, TBK1 and IKKε were knocked out, and in MEFs in which TNF and TBK1 were knocked out ( Fig. 5c ; Supplementary  Fig. 5a ). We therefore conclude that TBK1 and IKKε promote RIPK1 phosphorylation within the native TNFR1-SC.
Performing in vitro kinase assays to test whether TBK1 and IKKε can directly phosphorylate RIPK1 revealed that both kinases were able to do so (Fig. 5d,e) . A MS analysis of the in vitro kinase assay employing recombinant IKKε and RIPK1 in the presence of Nec-1s showed that RIPK1 was phosphorylated on numerous residues, as also confirmed by 2D gel electrophoresis ( Fig. 5f ; Supplementary  Fig. 5b ; Supplementary Table 4 ). Notably, several of these residues have been reported to be phosphorylated by other kinases [17] [18] [19] [20] .
Together, these results show that TBK1 and IKKε mediate RIPK1 phosphorylation on multiple residues in complex-I, thereby preventing RIPK1 autophosphorylation and the consequent formation of complex-II.
TBK1 and IKKε phosphorylate RIPK1 independently from
IKKα, IKKβ and MK2. TNF-induced RIPK1 activation is controlled by phosphorylation that is mediated by IKKα , IKKβ and MK2, all acting downstream of TAK1 [17] [18] [19] [20] . These phosphorylation events function as checkpoints to inhibit RIPK1-dependent complex-II formation. We next determined whether the TBK1-and IKKε -mediated RIPK1 phosphorylation represents a distinct cell death-preventing checkpoint. We purified the TNFR1-SC from cells treated with TNF together with different inhibitors or combinations thereof targeting TBK1 and IKKε (MRT), IKKα and IKKβ (TPCA-1), MK2 (PF-3644022) and TAK1 (7-oxozeanol) before treating the immunoprecipitated complexes with USP2 to visualize phosphorylation events. This analysis confirmed that inhibition of TAK1, MK2 and/or IKKα and IKKβ reduces RIPK1 phosphorylation in complex-I. Importantly, however, TBK1 and IKKε phosphorylated RIPK1 independently of MK2 and of IKKα and IKKβ , as only the combined inhibition of TBK1 and IKKε , either with that of TAK1 or with those of MK2 and IKKα and IKKβ , abrogated RIPK1 phosphorylation ( Fig. 5g) .
A 2D gel analysis of complex-I further revealed that several low-pI forms of RIPK1 disappeared after the addition of MRT in conditions under which all other known phosphorylation events are inhibited (Fig. 5h ). Thus, TBK1 and IKKε activity in complex-I promotes the phosphorylation of RIPK1 at multiple sites that are not phosphorylated by other RIPK1-inhibiting kinases. In line with a distinct checkpoint mediated by TBK1 and IKKε , their inhibition sensitized MEFs and L929 cells to RIPK1-dependent TNF-induced death even in the presence of MK2 and/or IKKα and IKKβ inhibitors (Fig. 5i,j) . Thus, TBK1 and IKKε -mediated RIPK1 phosphorylation constitutes a cell death checkpoint that is different from previously described ones. Furthermore, these results strongly suggest that TBK1 and IKKε directly phosphorylate RIPK1 in the TNFR1-SC.
TBK1 and IKKε protect against TNF-induced RIPK1-dependent lethal shock in vivo.
To reveal whether the cell death checkpoint identified herein is functionally relevant in vivo, we employed TNF at an established sublethal dose 17, 20 in a murine model of TNF-induced shock that requires RIPK1-dependent cell death 49, 50 . As expected, none of the mice succumbed following treatment with TNF alone. Strikingly, however, TNF and MRT co-treatment resulted in a highly significant reduction in survival, with 50% lethality only 8.5 h after injection and an overall survival of less than 20%. Importantly, concomitant RIPK1 inhibition completely prevented TNF and MRT-induced lethality (Fig. 5k ). Hence, inhibition of RIPK1 by TBK1 and IKKε is essential for protection against TNFinduced lethal shock.
NEMO-recruited TANK and NAP1 engage TBK1 and IKKε to the TNFR1-SC.
Having identified that the control of TNF-induced cell death by TBK1 and IKKε is essential, we determined the biochemical mechanism of their recruitment to complex-I. TBK1 and IKKε are known to associate with various adaptors that recruit them to different signalling platforms 29 . One such adaptor is TANK 51 , which is recruited to complex-I in a HOIP-dependent manner (Fig. 1) . Using TANK-deficient cells, we observed that IKKε recruitment was abrogated in these cells and that TBK1 recruitment was reduced but still occurred (Fig. 6a,b) . Thus, IKKε recruitment entirely relies on TANK, whereas TBK1 is recruited by TANK and at least one additional adaptor.
After ruling out optineurin, a suggested TNFR1-SC component 52 , as the protein responsible for TANK-independent TBK1 recruitment to complex-I ( Supplementary Fig. 6a ), we sought to identify the additional adaptor (or adaptors) for TBK1. We undertook this in an unbiased manner by studying the TBK1 interactome using TBK1-deficient cells re-expressing TAP-tagged TBK1 and performing an MS analysis on the affinity-purified TBK1. With NAP1, SINTBAD (also known as TBKBP1), TANK and TRAF2, this analysis only identified known TBK1 interactors 37 (Fig. 6c,d ; Supplementary Table 5 ). While TRAF2 was recruited via TRADD independently of HOIP, and SINTBAD was not identified in the complex (Fig. 6e ), NAP1 was recruited to complex-I in a LUBACdependent manner (Fig. 6e) . In HeLa and A549 cells that had both TANK and NAP1 knocked out, we observed that TBK1 recruitment was completely or nearly completely absent from these cells, respectively ( Fig. 6f; Supplementary Fig. 6b ). In line with these results, the absence of TANK and NAP1 increased the autophosphorylation of RIPK1 in complex-I ( Supplementary Fig. 6c ). Thus, TANK and NAP1 are both responsible for the vast majority of TBK1 recruitment to complex-I.
As TANK has been shown to interact with NEMO 53 , which is recruited to complex-I via M1 ubiquitin 36 , we next evaluated the role of NEMO in TANK recruitment. This revealed that NEMO not only recruits TANK but also NAP1 and, consequently, brings IKKε and TBK1 to complex-I in both A549 cells and MEFs (Fig. 6g,h; Supplementary Fig. 6d ). Moreover, re-expression of wildtype NEMO, but not of a deletion mutant unable to bind TANK 53 (NEMO ΔTBD ), restored the recruitment of TANK, NAP1, TBK1 and IKKε to complex-I (Fig. 6i) . Interestingly, IKKα and IKKβ deficiency or inhibition, as well as TAK1 inhibition, reduced TNFinduced TBK1 activation. The additional treatment with MRT further dampened this effect ( Supplementary Fig. 6e-g) . Thus, NEMO recruitment to complex-I, which is mostly, but not exclusively, M1 ubiquitin-dependent 34, 36, 54 , recruits TANK and NAP1. TANK1 in turn brings TBK1 and IKKε , while NAP1 brings TBK1 to the TNFR1-SC. Their activation is partly dependent on IKKα and IKKβ and on autophosphorylation.
Together, these results show that NEMO mediates the recruitment of both canonical and non-canonical IKKs to complex-I, which all provide essential checkpoints to RIPK1, preventing untoward TNF-induced death.
Discussion
A major focus of current research on TNF-induced cell death is placed on the regulation of RIPK1, the central kinase in this process. Various post-translational modifications of RIPK1 are at the core of this regulation 50, [55] [56] [57] [58] .
Currently, RIPK1 is thought to be kept in check in the cytosol under unstimulated conditions 59 . Following TNF stimulation, RIPK1 is recruited to complex-I 13 , where it is rapidly post-translationally modified, including by cIAP1-and cIAP2-mediated K63-, K11-and K48-linked ubiquitylation and LUBAC-catalysed M1 ubiquitylation. M1 ubiquitin promotes the complex-I recruitment of NEMO together with its associated kinases, IKKα and IKKβ . Apart from activating NF-κ B, IKKα and IKKβ inactivate RIPK1 by phosphorylation, preventing its translocation to complex-II. Recently, the existence of an additional cell death checkpoint involving the p38 MAPK target MK2 was described [18] [19] [20] .
While TBK1 and IKKε were shown to be activated after TNF stimulation 45, 52 , their function in TNF signalling remained enigmatic. Here, we identified a NEMO-dependent checkpoint that controls TNF-induced cell death by the TBK1-and IKKε -mediated phosphorylation of RIPK1, which is largely dependent on M1 ubiquitylation and functionally independent from known cell death checkpoints ( Supplementary Fig. 6h ). It was recently proposed that the TBK1-mediated phosphorylation of RIPK1 on T189 impairs its substrate-binding capacity 60 . Our results, however, show that TBK1 and IKKε phosphorylate RIPK1 on multiple residues. It therefore appears that the TBK1-and IKKε -mediated regulation of RIPK1 is more complex. Further investigation will be required to define the contribution of the different TBK1-and IKKε -mediated phosphorylation events in keeping RIPK1 in check.
Interestingly, TBK1-deficient mice are embryonically lethal at embryonic day 14.5 due to aberrant TNFR1-induced cell death 30, 31 , a phenotype similar, but not identical, to that of NEMO-deficient animals 44, 61 . Hence, it was initially assumed that TBK1 activates TNFinduced NF-κ B-dependent gene expression. However, preventing TBK1 and IKKε activity exerts only limited effects on TNF-induced gene expression. Instead, we discovered that by phosphorylating RIPK1 on multiple sites within complex-I, TBK1 and IKKε control a physiologically essential cell death checkpoint. Accordingly, their pharmacological inhibition or genetic ablation resulted in TNFinduced cell death, both in cell lines and in vivo, as a consequence of unleashed RIPK1 activity and aberrant complex-II formation.
With the aim of elucidating the mechanism of how TBK1 and IKKε exert their function, we made the surprising discovery that NEMO mediates TBK1 and IKKε activation in complex-I. Mechanistically, NEMO enables the recruitment of TANK, which brings both TBK1 and IKKε to the complex, and of NAP1, which brings in additional TBK1. These results are striking, as they demonstrate that NEMO serves an essential survival function beyond regulating IKKα and IKKβ . Intriguingly, NEMO was previously shown to exert cell death-preventing functions independently of NF-κ B 17, 62 . Our results provide an explanation for this observation, as the combined activities of IKKα and IKKβ , TAK1 and MK2, and TBK1 and IKKε are required to keep RIPK1 in check. Of note, NEMO mutations are causative for a spectrum of diseases, including incontinentia pigmenti, ectodermal dysplasia and immunodeficiency, which are thought to be caused by a deficiency in activating IKKα and IKKβ 63 . On the basis of our results, one may consider that aberrant TNF-induced cell death caused by the lack of TBK1 and IKKε activity may participate in disease progression in patients with certain NEMO mutations.
Our results prompt the question as to what could be the evolutionary advantage of having three distinct checkpoints all focused on RIPK1, a single component in the TNFR1 pathway. TNF is induced as one of the first cytokines in response to various cellular stressors 64 . It is tempting to speculate that this triple safeguard mechanism might serve to ensure that, should anything go wrong-perhaps as the result of a pathogen-mediated targeted intervention 65 -with any of three of the arguably most crucial signalling pathways for innate and adaptive immunity, this is sensed as early as possible during innate immune signalling. The inability to properly phosphorylate RIPK1 in response to TNF would serve this purpose, with the resulting outcome of TNF signalling, the untoward death of the cell, triggering an alternative route to inflammation.
We herein identified a crucial role for TBK1 and IKKε in preventing TNF-induced cell death. So far, these kinases have mainly been considered as modulators of gene expression, mostly in interferon responses 40, 41 and autophagy 66, 67 . However, certain pathologies have been associated with mutations or altered expression of TBK1 and IKKε , including neuroinflammatory diseases, for example amyotrophic lateral sclerosis or frontotemporal dementias 68 , and various types of cancer 69 . Based on our results, diseases caused by NEMO deficiency should be added to this list. It will be interesting to evaluate to which extent aberrant TNF-induced, RIPK1-mediated cell death caused by deregulated TBK1 and IKKε activity participates in the initiation or progression of these diseases.
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Methods
Recombinant proteins, cells and cell lines.
Human full-length GST (glutathione S-transferase)-RIPK1 was from Abnova, GST-IKKε was from ThermoFisher and GST-TBK1 was from Sigma-Aldrich. Untagged TNF, HA (human influenza hemagglutinin)-TNF and TAP-TNF were produced and purified as previously described 14 . Etanercept was purchased from Pfizer.
Wild-type cancer cell lines were purchased from the American Type Culture Collection. The generation and reconstitution of cancer cell lines with HOIP, TANK, NAP1, optineurin, NEMO, TBK1 and IKKε , or TNF knocked out, and the generation of the different knockout MEFs were performed as previously described 10, 14 . The single guide RNA sequences used are presented in Supplementary Table 6 . Newly generated knockout cells were validated by sequencing. A549 and HeLa cells were transduced to express a TAP-tagged form of RIPK3. Briefly, we used a carboxy-terminal TAP-tag consisting of a 2× Strep-tag II sequence followed by a PreScission cleavage site and 1× Flag-tag. The coding sequence of human RIPK3 was inserted into the retroviral MSCV vector, followed by an internal ribosome entry site and the open reading frame of enhanced green fluorescent protein (EGFP). This vector was transfected using Lipofectamine 2000 in Phoenix-AMPHO cells. One day after transfection, the medium was replaced, and viral supernatants were collected at days 2 and 3. Viral supernatants were passed through a 0.45-μ m filter, added to HeLa or A549 cells at 60% confluence in the presence of polybrene (6 μ g ml -1 ) before cells were subjected to spinfection (1300 × g, 45 min, 30 °C). EGFP-positive cells were isolated using MoFlo FACS (Beckman Coulter) to more than 95% purity 2 days after infection. HOIP knockout HeLa and A549 cells re-expressing HOIP WT , HOIP C885S , Empty pBabe or the MSCV vector, as well as TBK1 knockout A549 cells re-expressing TBK1 WT or TBK1 D135N , were generated as previously described 39 . A549 NEMO knockout cells were transduced with pBabe-puro to re-express NEMO WT or NEMO ΔTBD (200-250 amino acid deletion). Corresponding primers can be found in Supplementary  Table 6 . All cell lines were regularly tested for mycoplasma using a MycoAlert Mycoplasma Detection kit (Lonza).
Inhibitors and antibodies.
The following inhibitors were used at the indicated final concentration in vitro, unless otherwise specified in the figure or figure legends: MRT (2 µ M; Sigma-Aldrich); BX-795 (1 µ M; Invivogen); TPCA-1 (5 µ M; Tocris Bioscience); PF-3644022 (1 µ M; Tocris Bioscience); 7-oxozeanol (1 µ M; Tocris Bioscience); Nec-1s (10 µ M; Biovision); zVAD-FMK (20 µ M; Abcam); cycloheximide (0.5 μ g ml -1 ; Sigma-Aldrich).
All antibodies used in this study are listed in Supplementary Table 7 , including information regarding dilutions and validation.
Retroviral transduction of cells.
Coding sequences of HOIP WT , HOIP C885S , TBK1 WT or TBK1 D135N were inserted into the retroviral MSCV vector containing GFP as the selection marker. Following infection, cells were sorted using MoFlo FACS (Beckman Coulter).
Tandem affinity purification. Samples were directly lysed in the case of TBK1-TAP-expressing cells or corresponding control cells. For A549 cells expressing HOIP WT or with HOIP knocked out (7.5 × 10 8 cells each), cells were first stimulated with TAP-TNF for 15 min. Cells were subsequently solubilized in IP lysis buffer (30 mM Tris-HCl pH 7.4, 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 10% glycerol, 1% n-dodecyl-β -maltoside, 50 mM NaF, 5 mM Na 3 VO 4 , 1× Complete proteaseinhibitor cocktail (Roche)) and cleared by centrifugation (13,000 r.p.m., 30 min, 4 °C). Samples were then incubated overnight with 100 μ l of anti-Flag M2-Agarose beads (Sigma) and washed three times with IP lysis buffer. Proteins were eluted overnight in IP lysis buffer containing 150 μ g ml -1 3× Flag peptide (Sigma) and 20 U ml -1 PreScission Protease (GE Healthcare). Samples were subsequently subjected to a second affinity precipitation step using Strep-Tactin resin (QIAGEN) overnight at 4 °C and eluted with 5 mM biotin. Proteins were precipitated using a 2-D Clean-Up kit (GE Healthcare) and resuspended in ice-cold denaturation buffer (100 mM ammonium bicarbonate, 8 M urea). The samples were then reduced with 4 mM dithiothreitol (DTT) at 56 °C for 30 min, alkylated with 8 mM iodoacetamide at 22 °C in the dark, and 4 mM DTT was used to neutralize the excess of iodoacetamide. Proteins were digested first with endoproteinase Lys-C (Wako Chemicals) for 4 h at 37 °C. Subsequently, samples were diluted with 2 M urea, and further digested with sequencing-grade trypsin (Promega) for 15 h at 37 °C. Samples were desalted with microspin columns filled with SEM SS18V silica (The Nest Group), eluted with 50% acetonitrile 0.1% trifluoroacetic acid, evaporated to dryness at 30 °C, and resolubilized in 20 µ l water containing 10% formic acid. A total of 1 µ l of the resulting peptidic solution was used for liquid chromatography (LC)-MS analysis.
In vitro kinase assays. For the IKKε in vitro kinase assays, 250 ng of recombinant RIPK1 and 125 ng of recombinant IKKε were mixed in 30 µ l kinase buffer (20 mM HEPES pH 7.5, 10 mM MgCl 2 , 2 mM DTT, phosphatase inhibitor (PhosSTOP), EDTA-free protease inhibitor cocktail, 20 µ M ATP) and incubated for 30 min at 30 °C. For the TBK1 in vitro kinase assays, equal amounts of recombinant proteins were used (for example, 250 ng) of recombinant RIPK1 and TBK1. The incubation time was 2 h at 30 °C. The kinase buffer used was the same as for the IKKε kinase assay but included 100 mM NaCl and the ATP concentration was 100 µ M. Kinase reactions were denatured by the addition of 4× reducing sample buffer (200 µ M DTT).
For the MS experiment, 2 µ g of recombinant RIPK1 and 1 µ g of recombinant IKKƐ were used, and the assay was performed as described above. Proteins were separated and purified on an SDS-polyacrylamide gel electrophoresis (PAGE) gel. Respective protein bands were excised, and proteins were reduced with 5 mM tris(2-carboxyethyl)phosphine (TCEP) in 50 mM triethylammonium bicarbonate (TEAB) at 37 °C for 20 min, alkylated with 10 mM chloroacetamide in 50 mM TEAB at ambient temperature for 20 min in the dark, and digested with 1:10 trypsin to protein ratio in-gel at 37 °C for 4 h. Protein gel bands were redigested to extract any remaining peptides. Samples were evaporated to dryness at 30 °C and resolubilized in 0.1% formic acid.
Mass spectrometry. nLC-MS/MS was performed using a Q Exactive Orbitrap Plus interfaced to a Nanospray Flex ion source and coupled to an Easy-nLC 1000 (Thermo Scientific). Peptides were separated on a 24-cm fused silica emitter, 75-µ m diameter, packed in-house with Reprosil-Pur 200 C18-AQ, 2.4-µ m resin (Dr. Maisch) using a linear gradient from 5% to 30% acetonitrile/0.1% formic acid over 10 min (for TBK1 affinity purification (AP)-MS) or 30 min (for TNFR-SC AP-MS and kinase assays) at a flow rate of 250 nl min -1 . Precursor ions were measured in a data-dependent mode in the orbitrap analyser at a resolution of 70,000 and a target value of 3 × 10 6 ions. The ten most intense ions from each MS1 scan were isolated, fragmented in the higher-energy collisional dissociation cell, and measured in the orbitrap at a resolution of 17,500. The proteomic raw data have been deposited in the ProteomeXchange Consortium via the PRIDE 70 partner repository with the dataset identifiers PXD008497 (TNFR1-SC analysis), PXD010777 (TBK1 analysis) and PXD008518 (RIPK1 kinase assay). Analyses of these data are provided in Supplementary Tables 2, 4 and 5.
Protein and phosphosite identification. Raw data were analysed using MaxQuant v.1.5.2.8, where they were searched against the human UniProt database (http://www.uniprot.org/, downloaded 22 Oct 2015 (for TNFR-SC AP-MS) and 5 Oct 2017 (for TBK1 AP-MS and kinase assays)) using default settings. Carbamidomethylation of cysteine residues was set as the fixed modification, and oxidation of methionine residues and acetylation at amino termini were set as the variable modifications. Phosphorylation (STY) was set as a variable modification for the kinase assays. Enzyme specificity was set to trypsin with maximally two missed cleavages allowed. To ensure high confidence identifications, peptidespectrum matches, peptides and proteins were filtered at a less than 1% false discovery rate. Proteins identified with a single peptide were filtered out. Label-free quantification in MaxQuant was used to quantify the AP-MS data.
Processing of TNFR1-SC AP-MS data. Proteins quantified in unstimulated controls were regarded as contaminants and filtered out. Proteins detected in more than 15 experiments in the Contaminant Repository for Affinity Purification Mass Spectrometry Data (CRAPome) were filtered out. Proteins not present in the TNFstimulated parental cells were filtered out. A protein-protein interaction network was generated in the STRING protein-protein interaction database using known interactions from curated databases and experimentally determined using default settings. Proteins not connected in the interaction network were filtered out.
Processing of TBK1 AP-MS data. Proteins quantified in TBK1 knockout cells were filtered out. Proteins detected in more than 15 experiments in the CRAPome were filtered out. A protein-protein interaction network was generated in the STRING protein-protein interaction database using known interactions from curated databases and experimentally determined using default settings. Proteins not connected in the interaction network were filtered out.
Processing of RIPK1 kinase assay data. Three raw files for each sample type (50% of the first digestion, 10% of the second digestion and 90% of the second digestion) were searched and grouped in MaxQuant to produce one output file. Non-RIPK1 phosphosites were filtered out from the 'phosphoSTY.txt' results file. Phosphorylation profiles of RIPK1 with and without IKKε were compared. Phosphosites detected in RIPK1 + IKKε that were absent from RIPK1 alone were taken forward. Phosphosite localization was carried out using the 'Phospho (STY) Probabilities' column. Serine, threonine or tyrosine residues with the following probability values were identified as follows: probabilities of < 0.1 were considered not likely to be phosphorylated; probabilities of ≥ 0.1 and < 0.75 were considered to be possible phosphosites; and probabilities of ≥ 0.75 were considered to be likely phosphosites.
Cell activation and immunoprecipitation. For TNFR1-SC preparation, cells were washed with PBS, resuspended in serum-free medium and stimulated with FLAG-TNF or TAP-TNF for the indicated times. Cells were lysed in IP lysis buffer at 4 °C for 1 h. FLAG-TNF or TAP-TNF (500 ng) was added to the lysates of non-stimulated control samples. Subsequently, the lysates were centrifuged at 13,300 r.p.m. for 20 min and the TNFR1-SC was immunoprecipitated using M2-Agarose beads (Sigma) overnight at 4 °C. The following day, the beads were washed three times with IP lysis buffer (1 ml), and proteins were eluted by
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Data collection
Cell death was recorded with Incucyte and Cell Titer Glo assays were run on the Mithras LB 940.
For RNA seq libraries to be multiplexed in the same run were pooled in equimolar quantities, calculated from Qubit and Bioanalyser fragment analysis. Samples were sequenced on the NextSeq 500 instrument (Illumina, San Diego, US) using a either a 43bp or 81bp paired end run.
LC-MS/MS was performed on a Q Exactive Orbitrap Plus interfaced to a NANOSPRAY FLEX ion source and coupled to an Easy-nLC 1000 (Thermo Scientific). Peptides were separated on a 24 cm fused silica emitter, 75 μm diameter, packed in-house with Reprosil-Pur 200 C18-AQ, 2.4 μm resin (Dr. Maisch) using a linear gradient from 5% to 30% Acetonitrile/ 0.1% Formic acid over 10min (for TBK1 AP-MS) or 30 min (for TNFR-SC AP-MS and kinase assay), at a flow rate of 250 nL/min. Precursor ions were measured in a data-dependent mode in the orbitrap analyser at a resolution of 70,000 and a target value of 3e6 ions. The ten most intense ions from each MS1 scan were isolated, fragmented in the HCD cell, and measured in the orbitrap at a resolution of 17,500.
Data analysis
Quantifications were performed with Excel, ImageJ and GraphPad and statistical analysis with GraphPad. Images and figures were processed with Adobe Photoshop and Illustrator CS6, respectively.
For RNAseq analysis data were demultiplexed and converted to fastq files using Illumina's bcl2fastq Conversion Software v2.19. Next, the expression of Illumina paired RNA-Seq transcript counts was quantified using kallisto software65 and a GRCh38 transcript model. The data was imported to the R statistical environment and summarised at the gene level (i.e transcript counts summed) using tximport.
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Statistical transformations and analysis of differential expression were performed with DESeq271. Relevant transcripts were illustrated using BioVenn software.
For protein and phosphosite identification raw data were analysed with MaxQuant version 1.5.2.8 where they were searched against the human UniProt database (http://www.uniprot.org/, downloaded 22/10/2015 (for TNFR-SC AP-MS) and 05/10/2017 (for TBK1 AP-MS and kinase assay) using default settings. Label-free quantification in MaxQuant was used to quantify the AP-MS data.
For processing of the TNFR1-SC and TBK1 AP-MS data a protein-protein interaction network was generated in the STRING protein-protein interaction database using known interactions from curated databases and experimentally determined at default settings.
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The RNA-Seq dataset generated during the current study are available in the SRA repository and can be accessed by using the following BioProject accession: PRJNA422567 or SRA accession: SRP126844 (https://www.ncbi.nlm.nih.gov/Traces/study/?acc=SRP126844).
The proteomic data has been deposited on the ProteomeXchange Consortium via the PRIDE(ref) partner repository with the dataset identifier PXD008497 (TNFR1-SC analysis), PXD010777 (TBK1 analysis), and PXD008518 (RIPK1 kinase assay).
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Sample size
No statistical method was used to determine the correct sample size. Instead the sample sizes were determined based on our experiences from previous studies using similar methodologies.
Data exclusions No data was excluded from the study.
Replication
All biological experiments were carried out under clearly defined and standard conditions and were repeated at least twice whenever possible. All replication attempts were successful.
Randomization Mice were randomly allocated to experimental groups.
Blinding
In vivo experiment was done by a scientist blinded to the treatment schedule. The in vitro experiments were not carried out blinded but most of them were done in parallel by at least two researchers.
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